Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:BLPH
- CUSIP: N/A
- Web: www.bellerophon.com
Capitalization:- Market Cap: $39.77 million
- Outstanding Shares: 35,510,000
Average Prices:- 50 Day Moving Avg: $1.08
- 200 Day Moving Avg: $1.08
- 52 Week Range: $0.43 - $1.69
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.17
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($0.02) per share
- Price / Book: -56.00
Profitability:- EBIDTA: ($22,580,000.00)
- Return on Equity: -221.30%
- Return on Assets: -79.20%
Debt:- Current Ratio: 3.71%
- Quick Ratio: 3.71%
Misc:- Average Volume: 470,200 shs.
- Beta: -0.91
- Short Ratio: 10.76
Frequently Asked Questions for Bellerophon Therapeutics (NASDAQ:BLPH)
What is Bellerophon Therapeutics' stock symbol?
Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."
How were Bellerophon Therapeutics' earnings last quarter?
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) released its quarterly earnings results on Monday, August, 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.03. View Bellerophon Therapeutics' Earnings History.
When will Bellerophon Therapeutics make its next earnings announcement?
Where is Bellerophon Therapeutics' stock going? Where will Bellerophon Therapeutics' stock price be in 2017?
2 analysts have issued twelve-month price targets for Bellerophon Therapeutics' stock. Their forecasts range from $4.50 to $5.00. On average, they anticipate Bellerophon Therapeutics' share price to reach $4.75 in the next year. View Analyst Ratings for Bellerophon Therapeutics.
Who are some of Bellerophon Therapeutics' key competitors?
Some companies that are related to Bellerophon Therapeutics include Pfenex (PFNX), Ergomed PLC (ERGO), Rexahn Pharmaceuticals (RNN), Applied Genetic Technologies Corporation (AGTC), ImmuPharma PLC (IMM), Motif Bio PLC (MTFB), TRACON Pharmaceuticals (TCON), Flex Pharma (FLKS), Endocyte (ECYT), Microbot Medical (MBOT), vTv Therapeutics (VTVT), Dipexium Pharmaceuticals (PLXP), KemPharm (KMPH), Leap Therapeutics (LPTX), Xenon Pharmaceuticals (XENE), OptiBiotix Health PLC (OPTI), Capricor Therapeutics (CAPR) and Aldeyra Therapeutics (ALDX).
Who are Bellerophon Therapeutics' key executives?
Bellerophon Therapeutics' management team includes the folowing people:
- Jonathan M. Peacock, Chairman of the Board, President
- Fabian Tenenbaum, Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director
- Megan Schoeps, Principal Financial Officer
- Martin D. Meglasson Ph.D., Chief Scientific Officer, Vice President
- Reinilde Heyrman M.D., Vice President, Chief Clinical Development Officer and Secretary
- Martin Dekker, Vice President - Device Engineering
- Manesh Naidu, Vice President, Chief Business Officer
- Deborah A Quinn M.D., Vice President - Medical Lead for INOpulse Programs
- Daniel Tasse, Director
- Naseem Amin M.D., Independent Director
When did Bellerophon Therapeutics IPO?
(BLPH) raised $60 million in an IPO on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.
Who owns Bellerophon Therapeutics stock?
Bellerophon Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include New Mountain Vantage Advisers L.L.C. (29.78%), FMR LLC (3.36%), Susquehanna International Group LLP (2.76%) and Vanguard Group Inc. (1.86%). Company insiders that own Bellerophon Therapeutics stock include Jens Luehring and Jonathan M Peacock. View Institutional Ownership Trends for Bellerophon Therapeutics.
Who sold Bellerophon Therapeutics stock? Who is selling Bellerophon Therapeutics stock?
Who bought Bellerophon Therapeutics stock? Who is buying Bellerophon Therapeutics stock?
Bellerophon Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP and Vanguard Group Inc.. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Jens Luehring and Jonathan M Peacock. View Insider Buying and Selling for Bellerophon Therapeutics.
How do I buy Bellerophon Therapeutics stock?
Shares of Bellerophon Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bellerophon Therapeutics' stock price today?
One share of Bellerophon Therapeutics stock can currently be purchased for approximately $1.12.
MarketBeat Community Rating for Bellerophon Therapeutics (NASDAQ BLPH)MarketBeat's community ratings are surveys of what our community members think about Bellerophon Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Bellerophon Therapeutics (NASDAQ:BLPH)Earnings History by Quarter for Bellerophon Therapeutics (NASDAQ BLPH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.19) | | | | | N/A |  |
| 8/7/2017 | Q2 2017 | ($0.15) | ($0.12) | | | View | N/A | |
| 5/15/2017 | Q1 2017 | ($0.25) | ($0.15) | | | View | N/A | |
| 3/13/2017 | Q4 2016 | ($0.21) | ($0.37) | | | View | N/A | |
| 11/8/2016 | Q3 2016 | ($0.42) | ($0.30) | | | View | N/A | |
| 8/9/2016 | Q216 | ($0.51) | ($0.39) | | | View | N/A | |
| 5/10/2016 | Q116 | ($0.65) | ($0.54) | | | View | N/A | |
| 3/21/2016 | Q4 | ($1.06) | ($0.82) | | | View | Listen | |
| 11/12/2015 | Q315 | ($0.94) | ($0.86) | | | View | N/A | |
| 8/13/2015 | Q2 2015 | ($0.96) | ($0.90) | | | View | N/A | |
| 3/31/2015 | Q4 2014 | ($2.16) | ($1.62) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Bellerophon Therapeutics (NASDAQ:BLPH)2017 EPS Consensus Estimate: ($1.08)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q2 2017 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q3 2017 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q4 2017 | 1 | ($0.27) | ($0.27) | ($0.27) |
(Data provided by Zacks Investment Research)
Dividend History for Bellerophon Therapeutics (NASDAQ:BLPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Bellerophon Therapeutics (NASDAQ:BLPH)Insider Ownership Percentage: 60.40%
Institutional Ownership Percentage: 45.85%
Insider Trades by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/9/2016 | Jens Luehring | Director | Buy | 20,000 | $0.56 | $11,200.00 | |
| 5/17/2016 | Jonathan M Peacock | CEO | Buy | 5,000 | $1.37 | $6,850.00 | |
| 12/16/2015 | Jonathan M. Peacock | CEO | Buy | 20,300 | $2.75 | $55,825.00 | |
| 8/19/2015 | Jonathan M Peacock | CEO | Buy | 5,000 | $5.48 | $27,400.00 | |
| 5/20/2015 | Jonathan M Peacock | CEO | Buy | 5,560 | $8.69 | $48,316.40 | |
| 2/19/2015 | Daniel Tasse | Director | Buy | 25,000 | $12.00 | $300,000.00 | |
| 2/19/2015 | Jonathan M Peacock | CEO | Buy | 20,800 | $12.00 | $249,600.00 | |
| 2/19/2015 | Linde North America, Inc. | Major Shareholder | Buy | 358,916 | $12.00 | $4,306,992.00 | |
| 2/19/2015 | Manesh Naidu | Insider | Buy | 1,500 | $12.00 | $18,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Bellerophon Therapeutics (NASDAQ:BLPH)
Latest Headlines for Bellerophon Therapeutics (NASDAQ:BLPH)
| Source: |
|
| Date | Headline |
|---|
 | Zacks Investment Research Upgrades Bellerophon Therapeutics, Inc. (BLPH) to Buy
www.americanbankingnews.com - September 15 at 7:26 PM |
| Bellerophon Therapeutics, Inc. (BLPH) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - September 14 at 7:50 PM |
| -$0.22 EPS Expected for Bellerophon Therapeutics, Inc. (BLPH) This Quarter
www.americanbankingnews.com - September 13 at 9:30 AM |
| Bellerophon Therapeutics, Inc. (BLPH) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - September 9 at 11:18 AM |
| Bellerophon Therapeutics, Inc. (BLPH) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - September 7 at 7:06 PM |
 | Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences
finance.yahoo.com - September 7 at 4:49 PM |
| Zacks Investment Research Lowers Bellerophon Therapeutics, Inc. (BLPH) to Hold
www.americanbankingnews.com - September 6 at 7:44 PM |
| Bellerophon Therapeutics, Inc. (BLPH) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - September 6 at 7:40 AM |
 | Bellerophon Therapeutics (BLPH) Reports Positive Top Line Phase ... - StreetInsider.com
www.streetinsider.com - September 5 at 11:13 PM |
| Bellerophon Therapeutics (BLPH) Reports Positive Top Line Phase 2 Data of INOpulse for Treatment of PH-COPD
www.streetinsider.com - September 5 at 6:11 PM |
| Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
finance.yahoo.com - September 5 at 6:11 PM |
| Bellerophon shares surge 20% premarket on positive results in trial of COPD treatment
finance.yahoo.com - September 5 at 6:11 PM |
| Bellerophon Therapeutics, Inc. (BLPH) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - August 31 at 6:56 PM |
| Bellerophon Therapeutics, Inc. (BLPH) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - August 29 at 7:38 PM |
| Bellerophon Therapeutics, Inc. (BLPH) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - August 23 at 7:46 PM |
| Bellerophon Therapeutics, Inc. (BLPH) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - August 22 at 7:32 PM |
| Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - August 11 at 7:16 PM |
| Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Releases Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - August 8 at 10:51 AM |
 | Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - August 7 at 10:11 PM |
| Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 7 at 5:09 PM |
| Bellerophon Therapeutics posts 2Q loss
finance.yahoo.com - August 7 at 5:09 PM |
| Bellerophon (BLPH) Announces FDA Agreement on Phase 2b Study ... - StreetInsider.com
www.streetinsider.com - August 5 at 2:58 AM |
| Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
finance.yahoo.com - August 3 at 6:02 PM |
| Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 8:10 AM |
| Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - July 11 at 8:28 PM |
| Bellerophon Therapeutics Inc (BLPH) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - June 11 at 12:26 AM |
| Bellerophon Therapeutics, Inc. (BLPH)
finance.yahoo.com - May 29 at 4:14 PM |
 | Biotech Stocks Under Scanner -- Juno Therapeutics, Nektar Therapeutics, Threshold Pharma, and Bellerophon Therapeutics
www.bizjournals.com - May 25 at 10:04 PM |
 | Biotech Stocks Under Scanner -- Juno Therapeutics, Nektar ... - PR Newswire (press release)
www.prnewswire.com - May 25 at 5:01 PM |
| Bellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulse - StreetInsider.com
www.streetinsider.com - May 24 at 8:53 PM |
| Bellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulse
www.streetinsider.com - May 23 at 11:51 AM |
| Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference
finance.yahoo.com - May 23 at 11:51 AM |
| Bellerophon Therapeutics Inc (BLPH) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 16 at 3:24 PM |
| Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - May 15 at 9:41 AM |
| Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 15 at 9:40 AM |
| Bellerophon Therapeutics posts 1Q loss
finance.yahoo.com - May 15 at 9:40 AM |
 | BRIEF-Bellerophon to issue 2 mln registered shares of common stock
www.reuters.com - May 11 at 4:29 PM |
| Bellerophon Therapeutics (BLPH) Enters Agreement for $3M Registered Direct Offering of Common Stock, Warrants
www.streetinsider.com - May 11 at 9:15 AM |
| Bellerophon Announces $3.0 Million Registered Direct Offering
finance.yahoo.com - May 10 at 8:48 AM |
| Bellerophon Therapeutics Inc (BLPH) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 12:16 AM |
| Bellerophon Therapeutics Inc (BLPH) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - May 5 at 11:54 PM |
| Bellerophon Therapeutics (BLPH) Earns Daily News Impact Rating of 0.34
www.americanbankingnews.com - May 2 at 12:52 PM |
| Bellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATS - StreetInsider.com
www.streetinsider.com - May 2 at 11:49 AM |
| Bellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATS
www.streetinsider.com - May 1 at 3:57 PM |
| Bellerophon to Present Positive Clinical Data on INOpulse® at the American Thoracic Society 113th International Conference
finance.yahoo.com - May 1 at 9:09 AM |
| Bellerophon Therapeutics (BLPH) Getting Somewhat Negative Media Coverage, Report Finds
www.americanbankingnews.com - April 28 at 10:22 AM |
| Bellerophon Therapeutics (BLPH) Earning Somewhat Critical Media Coverage, Report Shows
www.americanbankingnews.com - April 24 at 6:08 PM |
| Bellerophon Therapeutics (BLPH) Getting Somewhat Negative Media Coverage, Analysis Finds
www.americanbankingnews.com - April 21 at 12:33 PM |
| Bellerophon Therapeutics Inc (BLPH) Short Interest Down 0.6% in March
www.americanbankingnews.com - April 20 at 7:54 PM |
| Bellerophon Therapeutics (BLPH) Given Daily Coverage Optimism Rating of 0.10
www.americanbankingnews.com - April 17 at 2:08 PM |
Bellerophon Therapeutics (BLPH) Chart for Friday, September, 22, 2017
